APOE and Cognitive impairment: It is said that APOE4 carriers demonstrate a low cerebral glucose metabolic rate, with no comorbid cognitive impairment and increased Aβ plaque accumulation, which makes the DCGM a marker of potential AD which begins several dozen years before cognitive debilitation is confirmed [69].